The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Oct 31, 2019. Its latest SEC filing is a SC 13G/A from Feb 10, 2020.
10-Q for Q3 FY2019, filed Oct 31, 2019
The sections below describe the company as of the FY2018 annual report.
Develops and manufactures pharmaceutical ingredients, intermediates and finished medicines for innovator and generic drug companies.
10-K for FY2018, filed Feb 13, 2019
Pharmaceutical customers pay Cambrex to develop and manufacture ingredients and finished medicines. Custom development projects and products made only for one customer can be paid for as work progresses; products that can be sold to multiple customers are generally paid for when shipped, and some customers pay in advance.
10-K for FY2018, filed Feb 13, 2019The Company’s business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic…View ↗
In most single-use product sales, a quantity is ordered and manufactured according to the customer’s specifications and is typically only…View ↗
The Company’s multi-use product sales can be sold to multiple customers and have an alternative use. Both the transaction sales price and…View ↗
The service revenue stream represents services provided to a customer to assist with early stages of the regulatory approval process. The…View ↗
Payment terms can vary by the type and location of the customer and the products or services offered. The term between invoicing and when…View ↗
$532.1M
10-K for FY2018, filed Feb 13, 2019
$532.1M ↗
Innovator and generic pharmaceutical companies buy Cambrex’s products and services. Sales are made directly and through independent sales agents, particularly agents serving generic ingredient customers outside the U.S. and Western Europe.
10-K for FY2018, filed Feb 13, 2019The Company’s business is primarily comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic…View ↗
The Company’s products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc.…View ↗
Marketing generally requires significant cooperative effort among a highly trained sales and marketing staff, a scientific staff that can…View ↗
10-K for FY2018, filed Feb 13, 2019
One customer from both the API and FDF segment, accounted for 24.8%, 35.1% and 36.9% of 2018, 2017 and 2016 consolidated gross sales…View ↗
Yes. It kept 17 cents of every revenue dollar as net income in FY2018 and turned 5 cents into free cash flow.
10-K for FY2018, filed Feb 13, 2019
10-K for FY2018, filed Feb 13, 2019
$101.5MView ↗
10-K for FY2018, filed Feb 13, 2019
$92.4MView ↗
10-K for FY2018, filed Feb 13, 2019
$24.4MView ↗
8-K, filed Dec 5, 2019
EAST RUTHERFORD, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) — Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug…View ↗
Grew. Revenue grew 42% in 4 years, from $374.6M in FY2014 to $532.1M in FY2018, about 9% a year.
Finished-dose manufacturing
The earlier report described finished-dose generics as a portfolio Cambrex was beginning to develop; the latest describes finished-dose products and services as part of its business and says the Halo acquisition added contract manufacturing capabilities.
10-K for FY2015, filed Feb 9, 2016 10-K for FY2018, filed Feb 13, 2019The Company recently began developing a portfolio of finished dosage form generic drug products and expects to eventually file abbreviated…View ↗
Loading...
